Tetra-cationic platinum(II) porphyrins like a candidate photosensitizers to bind, selective and drug delivery for metastatic melanoma

Couto, Gabriela Klein; Pacheco, Bruna Silveira; Borba, Victoria Mascarenhas; Rodrigues, João Carlos; Oliveira, Thaís Larré; Segatto, Natália Vieira; Seixas, Fabiana Kömmling; Acunha, Thiago V.; Iglesias, Bernardo A.; Collares, Tiago

doi:10.1016/j.jphotobiol.2019.111725

Cited by 31 publications

(10 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Using this approach, Couto and collaborators found novel candidates against metastatic melanoma, particularly tetra-cationic platinum(II) porphyrins. Obtained data suggested their affinity for the N-terminal region of Apolipoprotein B-100 of the low-density lipoprotein receptor [55]. Another study demonstrated the potential of valproic acid as a potential anticancer agent towards B16-F10 resistant melanoma cells.…”

Section: Structure-based Approachesmentioning

confidence: 95%

The Challenging Melanoma Landscape: From Early Drug Discovery to Clinical Approval

Matias

Pinho

Penetra

et al. 2021

Cells

View full text Add to dashboard Cite

Melanoma is recognized as the most dangerous type of skin cancer, with high mortality and resistance to currently used treatments. To overcome the limitations of the available therapeutic options, the discovery and development of new, more effective, and safer therapies is required. In this review, the different research steps involved in the process of antimelanoma drug evaluation and selection are explored, including information regarding in silico, in vitro, and in vivo experiments, as well as clinical trial phases. Details are given about the most used cell lines and assays to perform both two- and three-dimensional in vitro screening of drug candidates towards melanoma. For in vivo studies, murine models are, undoubtedly, the most widely used for assessing the therapeutic potential of new compounds and to study the underlying mechanisms of action. Here, the main melanoma murine models are described as well as other animal species. A section is dedicated to ongoing clinical studies, demonstrating the wide interest and successful efforts devoted to melanoma therapy, in particular at advanced stages of the disease, and a final section includes some considerations regarding approval for marketing by regulatory agencies. Overall, considerable commitment is being directed to the continuous development of optimized experimental models, important for the understanding of melanoma biology and for the evaluation and validation of novel therapeutic strategies.

show abstract

Section: Structure-based Approachesmentioning

confidence: 95%

The Challenging Melanoma Landscape: From Early Drug Discovery to Clinical Approval

Matias

Pinho

Penetra

et al. 2021

Cells

View full text Add to dashboard Cite

show abstract

“…In order to potentiate the action of these structures, conjugations with Pt II complexes were tried. The isomeric tetra -cationic(pyridyl)porphyrin Pt II complexes 6 and 7 ( Figure 4 ) possessed cytotoxicity against metastatic WM1366 cells under white-light irradiation, inducing apoptosis via the activation of caspase-3 and -9 and alteration of cell cytoskeleton actin [ 56 ]. In silico study indicated that these complexes could be employed to deliver drugs owing to the affinity to the N-terminal region of ApoB-100.…”

Section: Photoactive Monofunctional Pt II Complmentioning

confidence: 99%

Monofunctional Platinum(II) Anticancer Agents

Jin

Guo

et al. 2021

Pharmaceuticals

View full text Add to dashboard Cite

Platinum-based anticancer drugs represented by cisplatin play important roles in the treatment of various solid tumors. However, their applications are largely compromised by drug resistance and side effects. Much effort has been made to circumvent the drug resistance and general toxicity of these drugs. Among multifarious designs, monofunctional platinum(II) complexes with a general formula of [Pt(3A)Cl]+ (A: Ammonia or amine) stand out as a class of “non-traditional” anticancer agents hopeful to overcome the defects of current platinum drugs. This review aims to summarize the development of monofunctional platinum(II) complexes in recent years. They are classified into four categories: fluorescent complexes, photoactive complexes, targeted complexes, and miscellaneous complexes. The intention behind the designs is either to visualize the cellular distribution, or to reduce the side effects, or to improve the tumor selectivity, or inhibit the cancer cells through non-DNA targets. The information provided by this review may inspire researchers to conceive more innovative complexes with potent efficacy to shake off the drawbacks of platinum anticancer drugs.

show abstract

“…Concerning the modification of porphyrins and related compounds with platinum(II), most of the modifications reported in the literature describe the metalation of the tetrapyrrolic core with Pt(II) leading to the corresponding metalloporphyrinoid [ 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 ]. A literature survey also shows a considerable number of papers describing the preparation of porphyrin-platinum complexes by modification of peripheral moieties at meso positions, mainly by attachment of cyclometalated platinum units to pyridyl moieties [ 20 , 59 , 67 , 68 , 69 , 70 , 71 , 72 , 73 ]. Analogue synthetic approaches were also reported to modify corroles [ 74 , 75 ] and phthalocyanines [ 76 , 77 , 78 , 79 , 80 ].…”

Section: Introductionmentioning

confidence: 99%

Unraveling the Photodynamic Activity of Cationic Benzoporphyrin-Based Photosensitizers against Bladder Cancer Cells

et al. 2021

View full text Add to dashboard Cite

In this study, we report the preparation of new mono-charged benzoporphyrin complexes by reaction of the appropriate neutral benzoporphyrin with (2,2′-bipyridine)dichloroplatinum(II) and of the analogs’ derivatives synthesized through alkylation of the neutral scaffold with iodomethane. All derivatives were incorporated into polyvinylpyrrolidone (PVP) micelles. The ability of the resultant formulations to generate reactive oxygen species was evaluated, mainly the singlet oxygen formation. Then, the capability of the PVP formulations to act as photosensitizers against bladder cancer cells was assessed. Some of the studied formulations were the most active photosensitizers causing a decrease in HT-1376 cells’ viability. This creates an avenue to further studies related to bladder cancer cells.

show abstract

Tetra-cationic platinum(II) porphyrins like a candidate photosensitizers to bind, selective and drug delivery for metastatic melanoma

Cited by 31 publications

References 35 publications

The Challenging Melanoma Landscape: From Early Drug Discovery to Clinical Approval

The Challenging Melanoma Landscape: From Early Drug Discovery to Clinical Approval

Monofunctional Platinum(II) Anticancer Agents

Unraveling the Photodynamic Activity of Cationic Benzoporphyrin-Based Photosensitizers against Bladder Cancer Cells

Contact Info

Product

Resources

About